This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Malawi

  1. PATH is working with partners in Ghana, Kenya, Malawi, and Uganda to increase vaccine uptake and save lives.
    Published: April 2022
    Type: Article
  2. These case studies are designed to share country journeys to establish inpatient newborn care services and to provide practical guidance in low- and middle-income settings around the world. This series is comprised of four case studies conducted in Ethiopia, India, Malawi, and Rwanda, as well as a global overview document.
    Published: February 2022
    Type: Resource Page
  3. These case studies are designed to share country journeys to establish inpatient newborn care services and to provide practical guidance in low- and middle-income settings around the world. This series is comprised of four case studies conducted in Ethiopia, India, Malawi, and Rwanda, as well as a global overview document.
    Published: February 2022
    Type: Resource Page
  4. PATH and partners are helping countries make better investments in digital health by learning from those leading the way.
    Published: November 2021
    Type: Article
  5. Countries have to determine how to make the best use of limited resources. PATH uses health economics to inform countries' decisions about vaccines.
    Published: November 2021
    Type: Article
  6. Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included a feasibility and acceptability study with national stakeholders and healthcare providers in Ghana, Kenya, Malawi, Peru, Senegal, and Sri Lanka to assess their preferences for different hypothetical rotavirus vaccine options. These briefs provide an overview of the results in each of the study countries.
    Published: October 2021
    Type: Resource Page
  7. Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included: targeted analyses on the ideal age group for iNGRVs and potential future combination vaccine options, impact and cost effectiveness analyses, a feasibility and acceptability study with national stakeholders and healthcare providers in six countries, and a demand forecast. This brief provides a comprehensive summary of the results.
    Published: October 2021
    Type: Resource Page
  8. In places with limited testing capacity, environmental surveillance of sewage and surface water may offer early warnings of outbreaks.
    Published: October 2021
    Type: Article
  9. A great deal of knowledge already exists in the global health community regarding maternal, neonatal, and child health (MNCH) medical devices and the challenges/barriers they face. But this knowledge is currently scattered across a variety of donor, partner, country, and academic sources, and as a result, is not easily accessible to the broader community. As such, PATH—under the Market Dynamics for MNCH Medical Devices project (MD4MD)—conducted a rapid desk research exercise focused on compiling information that was either publicly available or easily accessible, including: published literature, multilateral organization resources (such as policy briefs, technical reports, and guidelines); implementing partner projects (such as assessments, landscapes, and technical reports); donor investment documents; and expert interviews with relevant project leads and medical device experts.This evidence review focuses on eight specific devices: (1) manual blood pressure cuff (sphygmomanometer); (2) electric bCPAP device; (3) neonatal resuscitation device; (4) x-ray radiography machine; (5) point-of-care hemoglobin meter; (6) infusion device; (7) ultrasound (app-based “pocket” devices); and (8) ultrasound (traditional portable devices).The goal of these documents is to (1) summarize for policymakers and health system leaders the most important barriers that MNCH devices face, and (2) highlight potential interventions and key knowledge gaps to prioritize with future investments.
    Published: July 2021
    Type: Resource Page
  10. Together with over 400 external stakeholders from across 50 countries, PATH has crafted a new institutional strategy that responds to the current crises we face as a global community, to the needs and priorities of our local partners, and to the resounding calls for the continued transformation of our sector. To bring our new strategy to life for our external partners, we’ve developed a strategy brochure. The brochure explains why PATH exists (our mission), what we will do (our priorities) and, perhaps most importantly, how we will do it (our change strategies).
    Published: June 2021
    Type: Resource Page
Load more